Combination of siRNA-Directed Gene Silencing with Cisplatin Reverses Drug Resistance in Human Non-Small Cell Lung Cancer by Ganesh, Shanthi et al.
Wayne State University
Pharmaceutical Sciences Faculty Publications Department of Pharmaceutical Sciences
7-30-2013
Combination of siRNA-Directed Gene Silencing
with Cisplatin Reverses Drug Resistance in Human
Non-Small Cell Lung Cancer
Shanthi Ganesh
Northeastern University
Arun K. Iyer
Northeastern University, arun.iyer@wayne.edu
Jan Weller
Novartis Institutes for Biomedical Research Inc.
David V. Morrissey
Novartis Institutes for Biomedical Research Inc.
Mansoor M. Amiji
Northeastern University
This Article is brought to you for free and open access by the Department of Pharmaceutical Sciences at DigitalCommons@WayneState. It has been
accepted for inclusion in Pharmaceutical Sciences Faculty Publications by an authorized administrator of DigitalCommons@WayneState.
Recommended Citation
Ganesh S, Iyer AK, Weller J, Morrissey DV, Amiji MM (2013). Combination of siRNA-directed gene silencing with cisplatin reverses
drug resistance in human non-small cell lung cancer. Molecular Therapy--Nucleic Acids 2, e110; doi:10.1038/mtna.2013.29
Available at: http://digitalcommons.wayne.edu/pharm_science/6
Citation: Molecular Therapy—Nucleic Acids (2013) 2, e110; doi:10.1038/mtna.2013.29
© 2013 The American Society of Gene & Cell Therapy All rights reserved 2162-2531/12
www.nature.com/mtna
Introduction
Lung cancer is known to be the most frequent cancer world-
wide and the incidence of this epidemic disease is continu-
ing to increase at 0.5% per year globally.1 In contrast to the 
significant reduction of mortality from heart disease, the 
survival rate of lung cancer patients has been at a plateau 
for almost three decades, with a relative 5-year survival rate 
of <18% in most countries. Because of the size and distri-
bution of lung cancer, the cytoreductive surgery is not very 
effective for this disease and therefore chemotherapy and/
or radiation are the only treatments of choice. Despite major 
advances in patient management, chemotherapy and radio-
therapy, nearly 80% of the patients still die within 1 year of 
diagnosis and long-term survival is obtained only in 5–10% 
of the cases.1
The major obstacle in lung cancer chemotherapy is the 
emergence of inherent and acquired drug resistance in can-
cer cells.2,3 The efficacy of chemotherapy is thus limited. To 
overcome this resistance, often higher doses of toxic antican-
cer drugs are administered to cancer patients, thus resulting 
in adverse side effects to healthy organs and tissues. In this 
regard, reversal of drug resistance is one of the most attrac-
tive ways to significantly enhance therapeutic efficacy in lung 
cancers.
Cancer cells become resistant to anticancer drugs by sev-
eral mechanisms.4 One well-studied mechanism is the pro-
nounced activity of efflux pumps such as ATP transporters, 
which efficiently pump the drugs out of tumor cells. This resis-
tance is called pump-mediated resistance and is conferred by 
at least two proteins such as P-glycoprotein (P-gp, encoded 
by the mdr1 gene) and the multidrug resistance (MDR)-
associated proteins (mrp1).2,5 In lung cancer samples, P-gp 
is known to be infrequently expressed,6 mdr1 mRNA expres-
sion was reported to be increased in 15–50% of tumors and 
the incidence of mrp1 gene expression is much higher (about 
80%) in small cell lung cancer (SCLC) samples.
A growing body of evidence also suggests that the drug 
resistance, not mediated by pump-related genes and pro-
teins are attributed primarily to the mechanisms responsi-
ble for the activation of antiapoptotic cellular defense. Most 
chemotherapeutic agents, including cisplatin, induces cell 
death by apoptosis.7 Cisplatin, together with a third-gener-
ation anticancer agent, is the standard regimen used in the 
first-line treatment of advanced non SCLC (NSCLC) in the 
clinic and has shown superior efficiency in multiple trials. 
It is believed that the DNA damage caused by the chemo-
therapeutic drugs induces the release of an enzyme that 
activates the caspases.8 Programmed cell death or apop-
tosis, is generally known to occur by the activation of cas-
pase family of enzymes that cleave cellular proteins.9–12 One 
class of molecules that block apoptosis by directly binding 
to caspases is the inhibitor of apoptosis proteins such as 
survivin.13,14 bcl-2 is also an antiapoptotic gene and overex-
pressed in variety of human tumors including NSCLC and 
involved in tumorigenesis and chemoresistance.12 It has 
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One of the most challenging aspects of lung cancer therapy is the rapid acquisition of multidrug-resistant (MDR) phenotype. 
One effective approach would be to identify and downregulate resistance-causing genes in tumors using small interfering 
RNAs (siRNAs) to increase the sensitivity of tumor cells to chemotherapeutic challenge. After identifying the overexpressed 
resistance-related antiapoptotic genes (survivin and bcl-2) in cisplatin-resistant cells, the siRNA sequences were designed 
and screened to select the most efficacious candidates. Modifications were introduced in them to minimize off-target effects. 
Subsequently, the combination of siRNA and cisplatin that gave the maximum synergy was identified in resistant cells. We then 
demonstrated that the combination treatment of the selected siRNAs and cisplatin encapsulated in CD44-targeting hyaluronic 
acid (HA)-based self-assembling nanosystems reversed the resistance to cisplatin and delayed the tumor growth significantly 
(growth inhibition increased from 30 to 60%) in cisplatin-resistant tumors. In addition, no abnormalities in body weights, liver 
enzyme levels or histopathology of liver/spleen tissues were observed in any of the treatment groups during the study period. 
Overall, we demonstrate that the combination of siRNA-mediated gene-silencing strategy with chemotherapeutic agents 
constitutes a valuable and safe approach for the treatment of MDR tumors.
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been shown that the overexpression of bcl-2 delays the 
onset of apoptosis induced by several chemotherapeutic 
drugs.11 Substantial evidence indicates that downregulation 
of antiapoptotic genes such as survivin and bcl-2 can sen-
sitize cancer cells to anticancer drugs.5,15–17 Post-transcrip-
tional silencing of MDR-related genes thus seems to be a 
promising strategy.18
Such an objective can be effectively achieved if the 
agents are safely and selectively delivered to tumors by 
utilizing the anatomical and pathophysiological abnormali-
ties of solid tumors.19,20 It has been well established that 
nanoparticle surface decorated with tumor targeting agents, 
such as antibodies and peptides, can also be exploited for 
active targeting to tumor cells.21,22 In the previous study, 
we demonstrated that the hyaluronic acid (HA)-based 
self-assembling nanoparticle system efficiently delivered 
small interfering RNA (siRNA) to multiple types of tumors 
that express high levels of CD44.23 In the current study, we 
utilized the HA-based nanosystems to efficiently deliver 
siRNAs and chemotherapeutic agent, cisplatin, to demon-
strate combination effect for reversing the multiprolonged 
MDR cellular defense for pronounced antitumor response. 
Anti-MDR strategies may thus show high levels of clinical 
efficacy when administered in combination with chemother-
apeutic regimens.
Results
NSCLC cells show resistance to cisplatin, but not to 
doxorubicin
As our goal was to reverse the resistance in lung cancer, a 
pair of NSCLC cells that are sensitive and resistant to cispla-
tin (A549/A549DDP) and a SCLC pair of cells that are sensi-
tive and resistant to doxorubicin (H69/H69AR), respectively 
were selected for the initial study. As previously reported, 
A549 and its resistant counterpart (A549DDP) demonstrated 
saturating levels of CD44 expression and thus exhibited effi-
cient gene downregulation when treated with siRNA encap-
sulated HA nanosystem.23 However, the apparent lower level 
expression of CD44 on H69AR (~90%) and H69 (~60%) cells 
led to lower level activity in H69AR and almost no activity 
in H69 cells even at higher siRNA concentrations.23 Due to 
the above observations, the primary focus of our study was 
directed on resistant/sensitive NSCLC cells.
In order to assess the resistance levels of cisplatin in 
NSCLC cells, cisplatin drug alone was tested in sensitive 
and resistant A549 cells. The half maximal inhibitory concen-
tration (IC50) (117 µmol/l) was found to be fivefold higher in 
resistant cells compared with the sensitive cells (Figure 1a). 
Likewise, the cisplatin resistance was also assessed in 
doxorubicin resistant/sensitive SCLC cells and found no dif-
ference in IC50’s (data not shown). In order to improve the 
Figure 1 Optimizing hyaluronic acid (HA)/cisplatin nanoparticles and identifying the resistant genes in drug-resistant cells. To 
determine the cisplatin resistance in resistant NSCLC cells, cisplatin drug was incubated with both sensitive and resistant cells (A549/
A549DDP) at various concentrations for 2 days. (a) Cell viability was assessed to determine the IC50 (half maximal inhibitory concentration). (b) 
To improve the delivery, cisplatin was encapsulated in 1,8-diaminooctane (ODA)-modified HA nanosystems with and without poly(ethylene 
glycol) (PEG) and characterized. (c) The cytotoxicity of HA-ODA and HA-ODA/PEG nanoparticles were measured with and without cisplatin 
along with cisplatin alone as a control in resistant A549DDP cells. In order to identify the resistant genes in NSCLC and SCLC cells, RNA was 
extracted from both resistant and sensitive cells. (d) With appropriate primers, the reverse transcription-PCR was run to identify the expression 
of resistant genes. NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer.
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delivery efficiency of cisplatin to the resistant A549DDP cells, 
we attempted cisplatin encapsulation in multiple types of 
lipid-functionalized HA derivatives. Among them, a C8 lipid-
modified derivative of HA, namely HA-1,8-diaminooctane 
(ODA), exhibited relatively high cisplatin encapsulation 
(~15% wt/wt) and was used for all future in vitro and in vivo 
evaluations (Figure 1b). The blank HA nanoparticles did not 
exhibit any toxicity in tested cells (Figure 1c). However, the 
cisplatin loaded in HA-ODA nanoparticles with and without 
polyethylene glycol (PEG) demonstrated slightly better IC50 
when compared with cisplatin alone in resistant A549DDP cells 
(Figure 1c).
Overexpression of pump and non-pump–mediated 
 resistant genes may be responsible for resistance in 
NSCLC and SCLC resistance cells
Using the appropriate primers that were specific for pump 
and non-pump–mediated resistant genes, reverse tran-
scription-PCR was run using the RNA extracted from both 
sensitive and resistant SCLC (H69/H69AR) and NSCLC 
(A549/A549DDP) cells (Figure 1d). Survivin is overexpressed 
in resistant cell lines (A549DDP and H69AR) compared with 
their sensitive counterparts (A549 and H69), whereas, the 
mrp-1 is expressed in both resistant and sensitive cell lines 
(A549, A549DDP, H69, H69AR) almost at the same levels. In 
addition to survivin and mrp1 genes, bcl-2 and mdr1 genes 
were also identified from this experiment. bcl-2 was slightly 
overexpressed in resistant A549 cells but the overall expres-
sion level was much lower than the survivin expression level 
in this cell line. Just like the mrp1, bcl-2 was expressed almost 
equally in both resistant and sensitive H69 cells. mdr1 was 
not expressed in sensitive cell lines, but slightly expressed 
in both the resistant cells. Despite the differential expres-
sion levels, all four genes were selected in this study to carry 
out combination experiments and to address both pump 
and non-pump–mediated resistance (Figure 1d). In order 
to downregulate the genes overexpressed in the resistance 
cells, highly efficacious, target specific siRNA sequences 
were selected by computational in silico methods using the 
BioPred algorithm.24
Selection of potent and specific siRNA sequences lead 
to efficient target knockdown in resistant cells
All possible siRNA sequences for the given target were 
passed through rigorous computational filtration process 
(involving potency and specificity filtration) using BioPred 
algorithm.24 Top four to five predicted most potent siRNAs 
(score >96%) were acquired for further in vitro analysis 
(Supplementary Figure S1a,b). These selected siRNA 
sequences were then tested in resistant A549DDP cells at 
series of concentrations to rank the potency (Figure 2a–d). 
Based on the activity in cells, two most potent sequences 
were selected, introduced modifications and retested in 
cells to confirm activity. The best-modified one was selected 
Figure 2 Screening small interfering RNAs (siRNAs) in resistant A549 cells to identify the most potent sequence based on the 
mRNA knockdown. A total of (a) five survivin, (b) four bcl-2, (c) four mdr1, and (d) four mrp1 unmodified siRNA sequences were screened 
at 3–4 different concentrations in A549DDP cells to rank the potency of the sequences.
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for in vivo evaluation. Five different unmodified survivin 
sequences were initially screened at four different concen-
trations using lipofectamine as the transfection agent in 
A549DDP cells to rank their potency (Figure 2a). Based on 
the activity, the two most potent sequences (#1 and #2) were 
selected for further modifications. A standard 2′-OMe modifi-
cation was introduced into these two sequences and tested 
again in cells to confirm the activity. Since the sequence 
#2 did not lose any activity after introducing the modifica-
tion, it was selected to test in vivo along with its unmodi-
fied version to make a choice (Figure 3a). Out of the four 
mrp1 siRNAs screened in cells, the best one showed only 
60% target knockdown even at 50 nmol/l concentration in 
cells (Figure 2d). The lower values may be attributed due 
to issues with the siRNA potency or its target. All four mdr1 
and bcl-2 sequences screened were found equally potent 
in cells (Figures 2b,c). The same 2′OMe modification was 
introduced into the best two bcl-2 sequences (#2 and #3) 
and tested in cells (Figure 3b). In this case, activity was 
slightly lost in cells when the modification was introduced in 
both the sequences. However, to reduce or minimize the off-
target/immune stimulatory effects coming from an unmodi-
fied sequence, the best-modified version was selected for 
in vivo studies.
Combination strategies involving downregulation of 
non-pump–mediated genes and cisplatin treatments 
lead to synergy in resistant A549 cells
Based on the previous knockdown studies, the survivin 
siRNA (um #2) sequence that gave >90% silencing was 
selected for initial combination studies. The IC50 of cisplatin 
determined from the previous cytotoxicity data (Figure 1a) 
and few concentrations below IC50 were used with siRNAs 
in the combination study. Cisplatin treatment was given 
either 24 hours post-siRNA treatment or together with 
siRNA treatment to see if the timing of cisplatin treatment 
affords any benefit to the synergistic effect (Figure 4a,b). 
The results of this study indicated that the combination of 
survivin downregulation (>90%) and cisplatin treatment (at 
IC50) was found to be more effective when compared with 
cisplatin alone treatment and the activity was very similar 
for both co-treatment as well as for treatments that were 
given apart from each other. These results suggest that the 
downregulation of one of the resistant genes may enhance 
the sensitivity of the cells to cisplatin. In addition to survivin 
siRNA, bcl-2, mdr1, and mrp1 siRNAs (um #2, 2, and 3) 
were also then included in the follow-up combination stud-
ies with cisplatin to identify the best combination that gives 
the highest cell killing. For these experiments, bcl-2 and 
mdr1 siRNAs sequence that gave ~90% knockdown, mrp1 
siRNA that gave the maximum knockdown (60%) were 
evaluated as described in the Materials and Methods. The 
combination of survivin and/or bcl-2 with cisplatin demon-
strated combination/synergistic effect but not the mrp1 and 
mdr1 siRNAs. Downregulation of both survivin and bcl-2 
together with cisplatin treatment showed slightly better cell-
killing effect compared with the single-agent combinations 
(survivin + cisplatin or bcl-2 + cisplatin) suggesting a higher 
level of reversal of resistance with the downregulation of 
both antiapoptotic genes (Figure 4c).
Figure 3 Introducing modifications to the selected small interfering RNA (siRNA) sequences and evaluating their activity. After 
introducing the modifications to (a) two best survivin sequences and (b) two bcl-2 siRNA sequences, they were tested again along with their 
unmodified counterparts in resistant A549DDP cells to compare the activity.
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Combination therapy with siRNA and cisplatin yields 
significantly better antitumor efficacy compared with the 
single-agent treatment
First, the unmodified and modified survivin and bcl-2 
sequences that were selected from in vitro screens (survivin: 
um #2 versus m #2, bcl-2: um #2 and 3 versus m#2 and 3 and 
control siRNA) were formulated in HA-PEI/HA-PEG nanopar-
ticles as described previously.23 The resulting nanoparticles 
with siRNA had a mean hydrodynamic diameter of 85 ± 7.5 nm 
and zeta potential of −10 ± 4.5 mV. These forumlations were 
then dosed at 0.5 mg/kg every day for three consecutive days 
in mice bearing resistant A549 tumors for assessing target 
knockdown at different timepoints (24, 72, and 120 hours after 
last dose) to pick the best possible sequence for the combi-
nation efficacy study. In the first target knockdown study, the 
unmodified survivin siRNA sequence gave only 15% target 
knockdown in tumors 24 hours after the last injection. How-
ever, the activity was increased to ~40% at 72 hours and this 
activity was still maintained for at least 120 hours  (Figure 5a). 
The non-targeting control siRNA (CTL) sequence in the same 
study did not show any target knockdown. The best-modified 
sequence selected from the in vitro screening (#2) was tested 
in the same tumor model in another study to compare the 
activity with the unmodified sequence. The activity of unmodi-
fied sequence was ~40% at 72 and 120 hours after the last 
injection, almost identical to the previous study. Whereas, the 
activity of the modified sequence was only about 25–35% at 
the doses tested, suggesting that there may be a slight loss 
of potency when the modification was introduced or it is also 
possible that there was some immune stimulatory effect dem-
onstrated by the unmodified sequence (Figure 5b). In the 
bcl-2 screening study, the best two sequences found in the 
in vitro study were tested along with the corresponding modi-
fied versions in the same resistant A549 tumors. The unmodi-
fied sequences (#2 and 3) gave about 55 and 40% target 
knockdown, respectively at 72-hour timepoint. The modified 
versions, however, gave only 20–30% activity at the same 
timepoint (Figure 5c). Based on the above in vivo, knockdown 
studies, the survivin #2 (m) and bcl-2 #2 (m) sequences were 
selected for the combination efficacy study to minimize any 
off-target effects associated with the unmodified sequences.
To determine the optimum cisplatin doses that are needed 
for the efficacy study, a pilot cisplatin efficacy study was 
run before performing the actual combination study (Figure 
6a). To check the activity of cisplatin encapsulated HA-ODA 
nanoparticles with and without PEG, mice bearing A549DDP 
tumors were grown and sorted out to accommodate four 
groups with five mice in each group. Mice were injected 
with either phosphate-buffered saline (PBS), cisplatin alone, 
HA-ODA/cisplatin and HA-ODA/HA-PEG/cisplatin nanopar-
ticles at 1 mg/kg, twice at 4 days apart. Mice treated with 
either cisplatin or HA-ODA/cisplatin or HA-ODA/PEG/cispla-
tin nanoparticels showed tumor growth inhibition compared 
with the PBS-treated group  (treatment-to-control ratio (T/C) 
Figure 4 Evaluating the combination effect of small interfering RNA (siRNA) and cisplatin treatment in A549DDP cells. Cells were 
treated first with survivin siRNA for 24 hours followed by (a) the cisplatin treatment at different concentrations or (b) co-treated simultaneously. 
Forty-eight hours after the cisplatin treatment, cell viability was evaluated by MTS assay. (c) In the follow-up study, the combination effect of 
siRNAs against survivin, bcl-2, mdr1, and mrp1 combined with cisplatin was evaluated using the method used in a.
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of 0.6–0.65). Out of these three groups, the HA-ODA/cispla-
tin nanoparticles tend to be slightly better than the other two 
in the efficacy curve at the early timepoints. Given this, the 
HA-ODA/cisplatin nanoparticle system was selected for the 
combination study.
Next, to run a pilot efficacy study to combine the survivin 
downregulation and cisplatin treatment, mice bearing A549DDP 
tumors were treated with PBS, cisplatin, HA-PEI/PEG/ sur-
vivin or combination of HA-PEI/PEG/survivin + cisplatin. As 
the activity of three consecutive siRNA doses sustained for 5 
days, the cisplatin treatment was given 72 hours after the third 
siRNA dose to accommodate the activity of both treatments 
 (Figure 6b). The second round of siRNA treatment started 5 
days after the last siRNA dose of the first round. There was 
tumor growth inhibition observed in mice that had survivin 
alone (~23%) or cisplatin alone (~46%) treatments. But the 
combination group showed significantly better growth inhibition 
(~65%) compared with PBS or either of the single-agent treat-
ment on day 17 (Figure 6c). The corresponding T/C values 
were 0.77, 0.60, and 0.35 suggesting that there was combina-
tion or synergistic effect to some extent with the combination 
treatment. It suggests that the cell death induction by an anti-
cancer drug in combination with the suppression of non-pump 
resistance is required for effective killing of drug-resistant 
cancer cells. However, the rate of tumor growth inhibition was 
slightly reduced after the second round of treatment (Figure 
6d). After two rounds of treatment, the growth inhibition was 
only 25% (T/C of 0.75) for survivin, 40% (T/C 0.6) for cisplatin, 
and 54% (T/C 0.46) for combination treatment. This may be 
due to the development of further resistance for treatments or 
doses that were not sufficiently high enough to kill all the cells. 
Based on the results, further modifications were incorporated 
in the study plan for the next efficacy study.
In the next efficacy study, two siRNAs (survivin and bcl-2) 
were used in combination with cisplatin to see if the efficacy 
could be improved by knocking down both gene expression 
levels before cisplatin treatment. In this study, in addition to two 
therapeutic siRNAs, a control siRNA was also used in the pres-
ence and absence of cisplatin treatment to eliminate any non-
specific activity. The dose regimen was also adjusted slightly 
from the previous efficacy study to accommodate the peak 
activity of both treatments in a shorter window (Figure 7a). 
As expected, the untreated tumors and mice that had control 
siRNA treatments displayed rapidly progressive tumor growth, 
whereas the tumors in animals that had therapeutic siRNA 
alone, cisplatin alone or combination treatments grew relatively 
slowly. After two rounds of cisplatin and siRNA treatments, 
(six siRNA doses and two cisplatin doses), the groups that had 
combination treatment (survivin + cisplatin, bcl-2 + cisplatin or 
survivin + bcl-2 + cisplatin) showed significantly better tumor 
growth inhibition compared with PBS or CTL group (Figure 7b) 
and the groups that had single-agent treatment (survivin, bcl-2, 
survivin + bcl-2 or cisplatin) with growth inhibition of 62% (T/C of 
0.38) for survivin + bcl-2 + cisplatin group, 58% (T/C of 0.42) for 
Figure 5 Survivin/bcl-2 knockdown in A549DDP tumors at different timepoints. Tumor-bearing mice were injected with (a) survivin siRNA 
(um) and (b) um versus m encapsulated hyaluronic acid-poly(ethyleneimine) (HA-PEI)/HA-poly(ethylene glycol) (HA-PEG) self-assembled 
nanoparticles at 0.5 mg/kg for 3 days. Tumors were harvested at different timepoints (24, 72, and 120 hours for a and 72 and 120 hours for b) 
to look at the target specific knockdown. (c) Similarly, two bcl-2 siRNA sequences (um and m) were encapsulated in the same HA system and 
treated the mice bearing the same tumors and monitored the target knockdown at 72 hours. CTL, non-targeting control siRNA.
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bcl-2+cisplatin group, and 52% (T/C 0.48) for survivin + cispla-
tin group. Knocking down both survivin and bcl-2 together with 
cisplatin treatment, although did not show significant difference 
in efficacy compared to the ones with single siRNA + cisplatin 
(survivin + cisplatin or bcl-2 + cisplatin) groups, the combina-
tion did however show much greater significant difference from 
its control groups. (survivin + bcl-2 + cisplatin versus survivin 
+ bcl-2; P = 0.02, survivin + cisplatin versus survivin; P = 0.07 
or bcl-2 + cisplatin versus bcl-2; P = 0.03 or cisplatin versus 
survivin + cisplatin; P = 0.07, cisplatin versus bcl-2 + cisplatin; 
P = 0.05, cisplatin versus survivin + bcl-2 + cisplatin; P = 0.01 
or PBS versus survivin + cisplatin; P = 0.01, PBS versus bcl-2 
+ cisplatin; P = 0.002, PBS versus survivin + bcl-2 + cisplatin; P 
= 0.0001). There was a slightly added benefit of knocking down 
both survivin and bcl-2 expression levels together with cispla-
tin treatment over either of the siRNA + cisplatin treatment in 
this study (62% growth inhibition versus 58 or 52% growth inhi-
bition) supporting the pattern that was found in in vitro study 
results (80 versus ~72% killing).
The tumor growth inhibition in mice that had only cisplatin 
treatment was 31% (T/C of 0.69) and it was 29% (T/C of 0.71) 
for mice that had CTL siRNA + cisplatin treatment. The siRNA 
treatment groups such as survivin alone, bcl-2 alone, and 
survivin+bcl-2 groups had 31, 31, and 30% growth inhibition 
(T/C values of 0.69, 0.69, and 0.70), respectively. The con-
trol group with no cisplatin had almost no difference in tumor 
growth from PBS-treated group. To see if the tumor growth inhi-
bition observed correlates with the knockdown levels, tumor 
samples collected at the end of the study were analyzed for 
survivin and bcl-2 specific knockdown (Figure 7c). There was 
about 30–40% survivin knockdown observed in tumors that 
had survivin or survivin + cisplatin or survivin + bcl-2 + cispla-
tin treatment and a similar level bcl-2 specific knockdown seen 
in mice that had bcl-2 alone or bcl-2 + cisplatin or bcl-2 + sur-
vivin + cisplatin treatment. All the tumors that had survivin (or 
bcl-2) treatment showed similar downregulation of either sur-
vivin or bcl-2; however, the ones that had the combination of 
survivin (or bcl-2) and cisplatin demonstrated the knockdown 
along with significant tumor growth inhibition compared with 
the single-agent treatment. Similarly, the tumors that had sur-
vivin + bcl-2 or survivin + bcl-2 + cisplatin treatment showed 
about the same levels of both survivin and bcl-2 downregu-
lation, but the group that had cisplatin showed the highest 
tumor growth inhibition compared with all the other groups in 
the study supports the effective combination strategy (Figure 
7c). This result suggests that the combination of survivin or 
bcl-2 or survivin + bcl-2 downregulation and cisplatin treat-
ment together demonstrated combination or synergistic effect. 
Again, the study results suggest that the combination of anti-
cancer drug with suppression of non-pump resistance seems 
to be required for effective killing of MDR cells. Alternatively, 
one could also say that by downregulating the overexpressed 
Figure 6 Effect of the combination of cisplatin treatment and survivin silencing on growth of resistant A549DDP tumors. (a) To find the 
optimum cisplatin dose and timing for the combination efficacy study, a pilot study was initially run with cisplatin or 1,8-diaminooctane-modified 
hyaluronic acid (HA-ODA)/cisplatin or HA-ODA/poly(ethylene-glycol) (PEG)/cisplatin at 1 mg/kg doses and monitored the tumor growth. Based 
on this study results and the previous knockdown study data, (b) an efficacy study was designed with synchronized dosing of small-interfering 
RNA (siRNA) and cisplatin. (c) As planned, A549DDP tumor-bearing mice were grouped and injected with either siRNA alone at 3 × 0.5 mg/kg 
or with cisplatin at 1 mg/kg or with siRNA and cisplatin (3 × 0.5 and 1 mg/kg) together and monitored the tumor growth after the first round of 
treatment. (d) The mice were injected with the second set of doses and monitored the tumor growth for another week.
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resistant gene/genes in this study, the resistance to cisplatin 
could be overcome to some extent. More exploration should 
be carried out to identify any other genes that could also con-
tribute to the resistance, the right set of dosing schedules and 
frequency of doses to improve the synergistic effect. Taken 
together, our findings provide strong evidence that by silenc-
ing resistance-related genes, higher levels of efficacy can be 
achieved with chemotherapeutic agents.
Cisplatin-resistant tumor-bearing mice well tolerated the 
combination treatments of siRNA and cisplatin with no 
adverse effects
During this study period, to monitor the safety of the for-
mulations, the body weights of the mice used in the study 
was measured. Following two rounds of treatments, there 
was no obvious weight loss (Figure 8a) seen in any of the 
groups suggesting that the formulations/nanoparticles that 
were used for treatment are reasonably safe. Mice toler-
ated the single as well as the combination treatments quite 
well. In addition, there was no elevation in liver enzyme lev-
els observed during the study period (Figure 8d). Aspartate 
transaminase (AST) and alanine transaminase (ALT) levels 
were at the background levels (as same as the levels noted 
for PBS-treated mice) on day 14, 48 hours after the first round 
of siRNA/cisplatin treatment. Similar results were also found 
at the end of the study point (day 21). Lactate dehydroge-
nase levels were also unchanged at both timepoints indicat-
ing a lack of damage to the liver. Histopathology of liver and 
spleen tissues of mice from each group in this study on day 
21 was found to be consistent with what is regarded as within 
normal limits (Figures 8b,c). Taken together, these results 
suggest that these treatments with HA/siRNA or HA/cisplatin 
nanoparticles were well tolerated by the mice with resistant 
tumors. Systemic administration of siRNA/cisplatin encap-
sulated HA nanoparticles thus provide safe and sequence 
specific inhibition of tumor growth in resistant tumor model.
Discussion
As discussed previously, the mechanisms of MDR is very 
complex and it is usually the synergistic result of a combi-
nation of several mechanisms. Overexpression of pump-
mediated genes or antiapoptotic molecules are some of the 
examples discussed earlier.16,17 Downregulating the genes 
Figure 7 Effect of combination of downregulation of two antiapoptotic genes (survivin and bcl-2) and cisplatin treatment. (a) Based on 
the previous study, the dose regimen was changed slightly to improve the outcome. Mice bearing A549DDP tumors were treated with nine different 
combinations as described (n = 5) for over 2 weeks and monitored the tumor growth and other safety measurements. (b) Comparing the antitumor 
efficacy of cisplatin-treated mice with survivin + cisplatin-treated mice, cisplatin-treated mice with bcl-2 + cisplatin-treated mice, cisplatin-treated 
mice with CTL siRNA + cisplatin-treated mice, cisplatin-treated mice with survivin + cisplatin and survivin + bcl-2 + cisplatin-treated mice. (c) The 
corresponding target knockdown (survivin and bcl-2) were also determined in the tumors collected at the end of the study. Tumor samples were 
collected 72 hours after last siRNA dose. CTL, non-targeting control siRNA; siRNA, small interfering RNA.
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that are overexpressed and known to be responsible for resis-
tance in those cells using siRNAs is potentially a powerful way 
of reversing the resistance.18 After downregulating the over-
expressed genes, one would hope that the resistance will be 
reversed and the tumors will become sensitive to the antican-
cer drug treatment. Since it is possible that the inhibition of only 
one contribution to cellular resistance may not be sufficient 
for overcoming all mechanisms of cancer cell resistance to 
chemotherapy, combination of more than one mechanism or 
attacking more than one gene might be an effective strategy.17
Given the differential expression levels of pump and non-
pump–mediated resistant genes in A549 and A549DDP pair, all 
were evaluated in the combination studies with cisplatin to under-
stand the pump and non-pump–mediated resistance mecha-
nism. Only, the combination of survivin and/bcl-2 with cisplatin 
demonstrated combination/synergistic effect but not the mrp1 
and mdr1 siRNAs. As these mdr1 and mrp1 genes are known 
to contribute to pump-mediated resistance, it makes sense that 
they are not associated with the antiapoptotic pathway regula-
tion. Downregulation of both survivin and bcl-2 together showed 
slightly better tumor cell-killing effect compared with the single-
agent combinations suggesting a possible reversal of resistance 
with downregulation of more than one gene expression.
Before evaluating these combinations in tumor-bear-
ing mice, multiple pilot studies were conducted to pick the 
optimum dose of cisplatin and siRNA to be used in the com-
bination studies. Dosing schedules were carefully chosen 
based on those pilot studies to accommodate the maximum 
combination effect achievable. Since the siRNA-mediated 
knockdown was much higher at 72 hours than earlier time-
points, the cisplatin dose was given at 72 hours after last 
siRNA dose to attain maximum possible synergy. Also, the 
knockdown activity lasted for 5 days according to the previ-
ous studies. As such, the second set of siRNA treatments 
started 5 days after the last siRNA dose. Although the results 
suggest that there is therapeutic benefit in the combination 
group compared with the single-agent group, the resistance 
was not completely reversed by these treatments. The treat-
ment schedules and frequency of treatments together with 
the data in this study suggest that a shorter treatment period 
to include both treatments may have a better outcome. As 
such, the second study was planned to incorporate this so 
that the siRNA-mediated knockdown coming from the first 
round of siRNA treatment will prevail until the effect com-
ing from the second set of siRNA treatments commenced. 
Combining siRNA (either survivin or bcl-2) and cisplatin treat-
ments clearly gave a significantly improved activity compared 
to single-agent treatment in the combination efficacy studies 
as noticed in the in vitro settings. Also, when both siRNAs are 
used in combination with cisplatin, the growth inhibition was 
Figure 8 Monitoring toxicity in mice that had single and combination treatments as described in Figure 7. (a) Percentage weight 
change during the study period, the histopathology of (b) livers and (c) spleens of mice from each group at the end of the study were 
monitored. (d) Liver enzyme levels such as AST, ALT, and LDH levels were also monitored at the end of study. ALT, alanine transaminase; 
AST, aspartate transaminase; CTL, non-targeting control siRNA; LDH, lactate dehydrogenase.
PBS
HA/cisplatin
HA/survivin
HA/survivin + HA/bcl-2
HA/bcl-2
HA/CTL + HA/cisplatin
HA/CTL
HA/survivin + HA/cisplatin
HA/survivin + HA/bcl-2 + HA/cisplatin
0
10
AST levels
20
30
40
50
60
U/
l
70
80
90
100
HA/bcl-2 + HA/cisplatin
PBS CTL Survivin Survivin + bcl-2bcl-2
Cisplatin CTL + cisplatin Survivin + cisplatin Survivin + bcl-2 +
cisplatin
bcl-2 + cisplatin
PBS CTL Survivin Survivin + bcl-2bcl-2
Cisplatin CTL + cisplatin Survivin + cisplatin Survivin + bcl-2 +
cisplatin
bcl-2 + cisplatin
−20
−15
−10
−5
0
8 10 12 14 16
Days postimplantation
Pe
rc
e
n
ta
ge
 w
ei
gh
t c
ha
ng
e
18 20 22
5
10
15
20
PB
S
CT
L
CT
L +
 cis cis
Su
rvi
vin bc
l-2
bc
l-2
 + 
cis
s +
 bc
l-2
s +
 bc
l-2
 + 
cis
No
n-t
um
or
s +
 cis
0
10
ALT levels
20
30
40
50
60
U/
l
70
80
90
100
PB
S
CT
L
CT
L +
 cis cis
Su
rvi
vin bc
l-2
bc
l-2
 + 
cis
s +
 bc
l-2
s +
 bc
l-2
 + 
cis
No
n-t
um
or
s +
 cis
0
20
40
60
80
100
120
140
160
180
200 LDH levels
U/
l
PB
S
CT
L
CT
L +
 cis cis
Su
rvi
vin bc
l-2
bc
l-2
 + 
cis
s +
 bc
l-2
s +
 bc
l-2
 + 
cis
No
n-t
um
or
s +
 cis
a
b
c
d
Molecular Therapy—Nucleic Acids
Combination Therapy for Resistant Lung Tumors
Ganesh et al.
10
the highest compared to single siRNA + cisplatin treatment. 
However, the results indicate that the resistance was still not 
completely reversed (tumor growth inhibition was increased 
from 30 to 60%). This may be due to the involvement of 
genes other than the ones that we tested. Exploring other 
gene involvement in drug resistance is thus critical. Despite 
the fact that, this combination strategy was tested in only one 
resistant cell line and there are other possible genes involved 
in the resistance mechanism other than the genes that we 
evaluated, our data suggest that sustained therapeutic ben-
efits can be obtained by combining siRNA treatments along 
with cisplatin treatment using nanoparticle-based delivery 
systems. Given the clinical experience suggesting very poor 
efficacy or no efficacy after development of resistance, com-
bination protocols predicted on these individual treatment 
modalities would be anticipated to provide superior clinical 
benefits with reduced toxicity burden to patients.
In addition to evaluating delivery and efficacy, it is also 
important to monitor the safety and tolerability of the nanopar-
ticles that are being used to deliver both siRNA and cisplatin 
in the efficacy studies. To address that, the parameters such 
as change in body weight, plasma levels of the liver enzymes 
(ALT and AST), and lactate dehydrogenase were measured 
and compared between the treatment groups. Both ALT and 
AST are aminotransferases. AST is found in a variety of tis-
sues including liver, heart, kidney, and brain. It is released into 
the serum when any of these tissues is damaged. It is there-
fore not a highly specific indicator of liver injury. Whereas the 
ALT is exclusively found in liver and it is released as a result of 
liver injury. Thus, it serves as a fairly specific indicator of liver 
status. To further characterize the efficacy and safety of this 
therapy, the histopathology of liver and spleen was also carried 
out and compared between the treatment groups. The results 
clearly suggested that the mice with resistant tumors well toler-
ated the current delivery system with both siRNA and cisplatin.
In contrast to other delivery systems available, the HA-
based targeted systems we used here is efficacious at low 
siRNA and cisplatin doses and can be used to deliver mul-
tiple siRNA sequences and multiple small molecule drugs. 
These systems can thus serve as potential therapeutics for 
the treatment of multiple diseases.
Materials and methods
Tumor cell lines and tumor establishment. Human non-small 
lung cancer cell line A549 and SCLC cell line H69 were obtained 
from ATCC (Manassas, VA). The corresponding resistant cell 
lines (A549DDP and H69AR) were obtained from MGH  (Bos-
ton, MA) and ATCC, respectively. Cells were grown in RPMI 
medium supplemented with 10% FBS. Animal procedures were 
performed according to a protocol approved by Northeastern 
University, Institutional Animal Care and Use Committee (NU-
IACUC). Tumor models were developed in nude mice. Five to 
six weeks old nude mice were injected subcutaneously with 
tumor cells A549 (5 × 106 cells + matrigel), A549DDP (1 × 107 cells) 
under the right shoulder. Tumor volume was measured at least 
once or twice a week to monitor the tumor growth/suppression.
Baseline cisplatin resistance in lung cancer cells. To mea-
sure the cytotoxicity of cisplatin, A549/A549DDP cells were 
incubated with cisplatin at concentrations ranging from 1,000 
up to 0.1 µmol/l for 2 days. The cellular cytotoxicity was 
assessed using MTS assay and expressed as % viable cells.
siRNA and chemotherapy combination. A range of cisplatin 
concentration at IC50 and below the IC50 was used together with 
the siRNAs in the first round of combination study. Out of the 
four sets of cells plated, two sets were transfected with survivin 
siRNA using lipofectamine at two different doses (1 and 10 
nmol/l). Twenty-four hours after the transfection, cisplatin was 
added to one set of designated cells that had siRNA, at its IC50 
concentration and few other concentrations below IC50. In paral-
lel, the third set of cells was incubated with cisplatin alone at the 
same doses. All samples were kept at 37 °C for 2 days after the 
cisplatin addition. To the last set of cells, siRNA and the drug 
were simultaneously added and incubated for 48 hours as pre-
viously described. In the follow-up study, the other siRNAs (siR-
NAs for other targets such as bcl-2, mdr1, and mrp1) were also 
included in the combination evaluation. In these studies, the 
cisplatin concentration was kept at 100 µmol/l and the siRNA 
concentration was kept at 10 nmol/l. As described before, the 
siRNA treatment was given first and incubated for 24 hours. 
Following this, cisplatin was added to the cells that contained 
siRNA and incubated for another 48 hours.
Target knockdown with therapeutic siRNAs. As described pre-
viously,23 the self-assembled nanoparticles were made with 
HA-PEI, HA-PEG, and siRNAs (survivin, bcl-2, and control 
siRNA). The siRNA-loaded nanoparticles were characterized 
using the dynamic light scatting instrument by measuring 
the size and charge. For target knockdown studies, A549DDP 
tumor-bearing mice were treated with survivin siRNA or CTL 
siRNA encapsulated in HA nanoparticles at 0.5 mg/kg for 3 
days. Tumors were harvested 24, 72, and 120 hours after the 
third dose. RNA was extracted from the tumors to analyze the 
mRNA knockdown by reverse transcription-quantitative PCR 
method. In another study, the above tested unmodified survivin 
siRNA sequence was injected into tumor-bearing mice along 
with the corresponding modified sequence. Knockdown was 
monitored 72 and 120 hours after the third dose. In a different 
study, 2 bcl-2 (um) and 2 bcl-2 (m) siRNA encapsulated HA 
nanoparticles were tested in the same tumor model to pick 
the best possible sequence for the combination efficacy study.
Cisplatin efficacy in A549-resistant tumors. To find the best HA-
lipid derivative that can encapsulate and release cisplatin effec-
tively, multiple HA derivatives (with lipids tail of chain length 
such as C4, C6, C8, C18, choline and PEI-modified versions) 
were initially tried and the HA conjugated to 1,8-diaminooc-
tane (designated as HA-ODA) was selected for further stud-
ies; 10 mg/ml of HA-ODA solution was made in water. Likewise, 
10 mg/ml cisplatin solution was also made in DMSO; 90 µl of the 
HA-ODA and 10 µl of the cisplatin were mixed well to form HA-
ODA/cisplatin self-assembled nanoparticles. Along with this, 
HA-ODA solution was mixed with equal volume of HA-PEG (at 
10 mg/ml) and then with cisplatin solution in the following vol-
ume ratio (0.9:0.9:0.2). All the nanoparticle formulations were 
kept at room temperature for 15–20 minutes for nanoparticle 
stabilization. Four groups of mice (n = 5) with A549DDP tumors 
received total of two doses of either free cisplatin or HA-ODA/
cisplatin or HA-ODA/PEG/cisplatin at 1 mg/kg at 4 days apart. 
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Tumor volumes were measured using the following formula to 
monitor the tumor growth inhibition: Tumor volume = (length × 
width/width)/2. The growth inhibitory effect was estimated using 
the T/C ratio.
Combination efficacy studies with survivin/bcl-2 knockdown 
and cisplatin treatment. In the first study, five groups of mice 
(n = 5) with A549DDP tumors received doses of PBS (control) or 
cisplatin or HA-PEI/PEG/survivin siRNA or HA-PEI/PEG/sur-
vivin siRNA + cisplatin at the doses described. siRNA doses 
were given at 0.5 mg/kg for 3 days. Seventy-two hours after the 
last siRNA dose, cisplatin dose was given at 1 mg/kg. The sec-
ond round of treatments was initiated 72 hours after the cispla-
tin dose and repeated with the same pattern. Tumor volumes 
were monitored during the study period at least twice a week. In 
the next efficacy study, 10 groups of mice (n = 5) with A549DDP 
tumors received doses of different derivatives as described in 
the study design. In this study, both survivin and bcl-2 siRNAs 
in HA nanoparticles were used as single agent with and without 
cisplatin in HA nanoparticles and also used together to down-
regulate both genes at once with and without cisplatin. Unlike 
the first study, here the first cisplatin treatment was initiated 48 
hours after the last siRNA dose and the second round of treat-
ments were initiated 24 hours after cisplatin treatment. Tumor 
volume measurements were taken throughout the whole study 
to monitor the tumor growth/suppression. Tumors were col-
lected 72 hours after last siRNA treatment and analyzed the 
survivin and bcl-2 levels as described before.
Measuring body weight changes, liver enzyme levels and histo-
pathology. In the second efficacy study, in addition to the treat-
ment groups (n = 5), three additional mice with tumors were 
used in each group to monitor acute toxicity/safety. These mice 
were given the same treatment as the mice in the efficacy 
study groups. Mice were weighed the day the treatments com-
menced and every day during the dosing period. Body weights 
were taken continuously throughout the whole study period.
To measure the liver enzyme levels, the blood was collected, 
48 hours after the first round of treatment (three doses of HA/
siRNA and one dose of cisplatin) from all 10 groups (n = 3/
group). Also, at the end of the efficacy study, a terminal bleed 
was done to collect blood from all ten groups (n = 5) to look at 
the liver enzyme levels (both ALT and AST) and lactate dehy-
drogenase levels after two rounds of treatment using the man-
ufacturer’s instructions. Liver and spleen samples from mice 
were also collected for histopathological analysis at the end of 
the study (n = 5). The tissue samples analysis was performed 
at Tufts University Veterinary School (Grafton, MA).
Supplementary material
Figure S1. Selection of siRNA sequences using computa-
tional in silico methods.
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